Biomerica Q3 net sales drop 12% to $987,000

• Biomerica posted a net loss of USD 2.63 million for the nine months ended Feb. 28, 2026.
• Net sales fell 22% to USD 3.58 million on lower contract manufacturing revenue following completion of a prior R&D project.
• Cost of sales eased to USD 3.15 million, while it climbed 4 percentage points to 88% of net sales due to product mix and lower volume.
• Liquidity weakened, with cash and cash equivalents down to USD 1.34 million from USD 2.4 million at May 31, 2025, while an ATM program generated net proceeds of about USD 1.46 million.
• Management said cash is insufficient to meet operating requirements and strategic growth objectives over the next 12 months, and it is pursuing higher sales, expense cuts, asset sales, financing, and other strategic alternatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-016388), on April 13, 2026, and is solely responsible for the information contained therein.